NU 2013-149 INVENTORS
SHORT DESCRIPTION
This technology uses a low-dose combination of two FDA-approved compounds to reduce oxidative stress in neurons and slow disease progression in early stage Parkinson’s disease. BACKGROUND
Parkinson’s disease affects millions and there are currently no disease-modifying therapies. Existing treatments mainly manage symptoms but often cause significant side effects. The high costs and limited efficacy of current options highlight the need for innovative approaches that address the underlying process of neurodegeneration. ABSTRACT
This invention combines a dihydropyridine-based calcium channel inhibitor with a monoamine oxidase/nitric oxide synthase inhibitor in a low-dose formulation. The combination targets Cav1.3 channels and attenuates the consequences of nitric oxide signaling to lower oxidative stress, mitigating dopaminergic neuron loss in early stage Parkinson’s disease. In vivo laboratory studies validate the treatment's potential to slow disease progression effectively. MARKET OPPORTUNITY
Parkinson’s disease affects over one million people in the U.S., with roughly 90,000 new diagnoses each year. As the neurological therapeutics market expands, driven by an aging population and the lack of disease-modifying treatments, this innovative combination therapy offers a strategic commercial opportunity. DEVELOPMENT STAGE
TRL-3, Experimental Proof-of-Concept: Laboratory studies have validated the potential of this combination approach in reducing oxidative stress linked to Parkinson’s disease. APPLICATIONS
ADVANTAGES
IP STATUS
Issued US Patent 9,463,186
Combination of low dose isradipine and rasagiline is more effective than either alone. FIG. 9a —Mouse with two s.c. osmotic minipumps; drugs were given for 1 week prior to sacrifice. FIG. 9b —Box plots summarizing mitochondrial oxidant stress measurements in SNc DA neurons in ex vivo brain slices from mice given drugs alone or in combination. N>4 in each group.